|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wani MA, Jan FA, Khan NA, Pandita KK,
Khurshid R and Khan SH: Cancer trends in Kashmir; common types,
site incidence and demographic profiles: National Cancer Registry
2000-2012. Indian J Cancer. 51:133–137. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Qureshi MA, Khan SM, Masoodi MA, Qureshi
U, Ain Q, Jan Y, Haq I and Sheikh ZA: Epidemiology of cancers in
Kashmir, India: An analysis of hospital data. Adv Prev Med.
2016(1896761)2016. View Article : Google Scholar
|
|
4
|
Malvia S, Bagadi SA, Dubey US and Saxena
S: Epidemiology of breast cancer in Indian women. Asia Pac J Clin
Oncol. 13:289–295. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature 490: 61-70,
2012.
|
|
6
|
Garnett MJ and Marais R: Guilty as
charged: B-RAF is a human oncogene. Cancer Cell. 6:313–319.
2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hall RD and Kudchadkar RR: BRAF mutations:
Signalling, epidemiology, and clinical experience in multiple
malignancies. Cancer Control. 21:221–230. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hollestelle A, Elstrodt F, Nagel JH,
Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or
RAS pathway mutations in human breast cancer cell lines. Mol Cancer
Res. 5:195–201. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tilch E, Seidens T, Cocciardi S, Reid LE,
Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR and
Chenevix Trench G: Mutations in EGFR, BRAF and RAS are rare in
triple-negative and basal-like breast cancers from Caucasian women.
Breast Cancer Res Treat. 143:385–392. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Santarpia L, Qi Y, Stemke-Hale K, Wang B,
Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B,
Pippen J, et al: Mutation profiling identifies numerous rare drug
targets and distinct mutation patterns in different clinical
subtypes of breast cancers. Breast Cancer Res Treat. 134:333–343.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sapio MR, Posca D, Troncone G, Pettinato
G, Palombini L, Rossi G, Fenzi G and Vitale M: Detection of BRAF
mutation in thyroid papillary carcinomas by mutant allele-specific
PCR amplification (MASA). Eur J Endocrinol. 154:341–348.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Eachkoti R, Farooq S, Syeed SI, Wani HA,
Majid S and Pampori MR: Prevalence and prognostic relevance of
BrafV600E mutation in colorectal carcinomas from Kashmir (North
India) valley. Mutagenesis. 33:225–230. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bui MM, Riben MW, Allison KH, Chlipala E,
Colasacco C, Kahn AG, Lacchetti C, Madabhushi A, Pantanowitz L,
Salama ME, et al: Quantitative image analysis of human epidermal
growth factor receptor 2 immunohistochemistry for breast cancer:
Guideline from the college of american pathologists. Arch Pathol
Lab Med. Jan 15. 2019.(Epub ahead of print). PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fan H and Gulley ML: DNA extraction from
fresh or frozen tissues. Methods Mol Med. 49:5–10. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
El-Osta H, Falchook G, Tsimberidou A, Hong
D, Naing A, Kim K, Wen S, Janku F and Kurzrock R: BRAF mutations in
advanced cancers: Clinical characteristics and outcomes. PLoS One.
6(e25806)2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tiacci E, Trifonov V, Schiavoni G, Holmes
A, Kern W, Martelli MF, Pucciarini A, Bigerna B, Pacini R, Wells
VA, et al: BRAF mutations in hairy-cell leukemia. N Engl J Med.
364:2305–2315. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jung YY, Jung WH and Koo JS: BRAF mutation
in breast cancer by BRAF V600E mutation-specific antibody. Int J
Clin Exp Pathol. 9:1545–1556. 2016.
|
|
19
|
Turski ML, Vidwans SJ, Janku F,
Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J and
Kurzrock R: Genomically driven tumors and actionability across
histologies: BRAF-Mutant cancers as a paradigm. Mol Cancer Ther.
15:533–547. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bösmüller H, Fischer A, Pham DL, Fehm T,
Capper D, von Deimling A, Bonzheim I, Staebler A and Fend F:
Detection of the BRAF V600E mutation in serous ovarian tumors: A
comparative analysis of immunohistochemistry with a
mutation-specific monoclonal antibody and allele-specific PCR. Hum
Pathol. 44:329–335. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
COSMIC: Catalogue of Somatic Mutations in
Cancer. Wellcome Trust Sanger Institute; http://cancer.sanger.ac.uk/cancer-genome/projects/cosmic.
Accessed January 2, 2014.
|
|
22
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomized controlled trial.
Lancet. 380:358–365. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tafinlar® receives FDA
Breakthrough Therapy designation for non-small cell lung cancer
with BRAF mutation. GlaxoSmithKline, London, 2013. http://us.gsk.com/en-us/media/press-releases/2014/tafinlar-receives-FDA-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/"ref-label" rowspan="1" colspan="1">
26
|
Kim KB, Cabanillas ME, Lazar AJ, Williams
MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical
responses to vemurafenib in patients with metastatic papillary
thyroid cancer harboring BRAF(V600E) mutation. Thyroid.
23:1277–1283. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Falchook GS, Trent JC, Heinrich MC,
Beadling C, Patterson J, Bastida CC, Blackman SC and Kurzrock R:
BRAF mutant gastrointestinal stromal tumor: First report of
regression with BRAF inhibitor dabrafenib (GSK2118436) and whole
exomic sequencing for analysis of acquired resistance. Oncotarget.
4:310–315. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Robinson GW, Orr BA and Gajjar A: Complete
clinical regression of a BRAF V600E-mutant pediatric glioblastoma
multiforme after BRAF inhibitor therapy. BMC Cancer.
14(258)2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Bautista F, Paci A, Minard-Colin V, Dufour
C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D and Geoerger B:
Vemurafenib in pediatric patients with BRAFV600E mutated high-grade
gliomas. Pediatr Blood Cancer. 61:1101–1103. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Samuel J, Macip S and Dyer MJ: Efficacy of
vemurafenib in hairy-cell leukemia. N Engl J Med. 370:286–288.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Munoz J, Janku F, Cohen PR and Kurzrock R:
Erdheim-Chester disease: Characteristics and management. Mayo Clin
Proc. 89:985–996. 2014.PubMed/NCBI View Article : Google Scholar
|
